A Randomized Controlled Trial of ProstAtak™ as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak™ arm versus the placebo control arm. The analyses will be based on the intent to treat population.
Assessed at each visit every 6 months through year 5 until event occurs.
No
United States: Food and Drug Administration
PrTK03
NCT01436968
September 2011
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
University of New Mexico Cancer Center | Albuquerque, New Mexico 87131-5636 |
Arizona Oncology Services Foundation | Phoenix, Arizona 85013 |
University of Massachusetts Medical School | Worcester, Massachusetts 01605 |
Walter Reed National Military Medical Center | Bethesda, Maryland 20889 |
Genitourinary Surgical Consultants | Denver, Colorado 80220 |
Advanced Urology | Parker, Colorado 80134 |
The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland 21231 |
Texas Urology Specialists | Tomball, Texas 77375 |
Foothills Urology | Golden, Colorado 80401 |
Dr. Ned Stein's Office | Houston, Texas 77074 |
Dr. Irving Fishman's Office | Houston, Texas 77030 |